# Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

> **NCT01789723** · PHASE1 · WITHDRAWN · sponsor: **Acrotech Biopharma Inc.**

## Conditions studied

- Non Hodgkin's Lymphoma

## Interventions

- **DRUG:** Fusilev
- **DRUG:** Folotyn

## Key facts

- **NCT ID:** NCT01789723
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-03
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01789723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01789723, "Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01789723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*